

EXHIBIT A

FORM NRC-313M (8-78) 10 CFR 35	U.S. NUCLEAR REGULATORY COMMISSION APPLICATION FOR MATERIALS LICENSE – MEDICAL	Approved: GAO R0557																																												
INSTRUCTIONS – Complete Items 1 through 26 if this is an initial application or an application for renewal of a license. Use supplemental sheets where necessary. Item 26 must be completed on all applications and signed. Retain one copy. Submit original and one copy of entire application to: Director, Office of Nuclear Materials Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555. Upon approval of this application, the applicant will receive a Materials License. An NRC Materials License is issued in accordance with the general requirements contained in Title 10, Code of Federal Regulations, Part 30, and the Licensee is subject to Title 10, Code of Federal Regulations, Parts 19, 20 and 35 and the license fee provision of Title 10, Code of Federal Regulations, Part 170. The license fee category should be stated in Item 26 and the appropriate fee enclosed.																																														
1.a. NAME AND MAILING ADDRESS OF APPLICANT (institution, firm, clinic, physician, etc.) INCLUDE ZIP CODE Veterans Administration Medical Center Lyons, N. J. 07939 TELEPHONE NO.: AREA CODE() _____	1.b. STREET ADDRESS(ES) AT WHICH RADIOACTIVE MATERIAL WILL BE USED (if different from 1.a.) INCLUDE ZIP CODE (Same)																																													
2. PERSON TO CONTACT REGARDING THIS APPLICATION A. Paul Kidd Medical Center Director, 647-0180 TELEPHONE NO.: AREA CODE(201) _____	3. THIS IS AN APPLICATION FOR: (Check appropriate item) a. <input type="checkbox"/> NEW LICENSE b. <input checked="" type="checkbox"/> AMENDMENT TO LICENSE NO. <u>29-17045-01</u> c. <input type="checkbox"/> RENEWAL OF LICENSE NO. _____																																													
4. INDIVIDUAL USERS (Name individuals who will use or directly supervise use of radioactive material. Complete Supplements A and B for each individual.) Arnold Olefson, M.D.	5. RADIATION SAFETY OFFICER (RSO) (Name of person designated as radiation safety officer. If other than individual user, complete resume of training and experience as in Supplement A.) Arnold Olefson, M.D.																																													
6.a. RADIOACTIVE MATERIAL FOR MEDICAL USE																																														
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 40%;">RADIOACTIVE MATERIAL LISTED IN:</th> <th style="width: 10%;">ITEMS DESIRED "X"</th> <th style="width: 10%;">MAXIMUM POSSESSION LIMITS (In millicuries)</th> </tr> </thead> <tbody> <tr> <td>10 CFR 31.11 FOR IN VITRO STUDIES</td> <td></td> <td></td> </tr> <tr> <td>10 CFR 35.100, SCHEDULE A, GROUP I</td> <td></td> <td>AS NEEDED</td> </tr> <tr> <td>10 CFR 35.100, SCHEDULE A, GROUP II</td> <td></td> <td>AS NEEDED</td> </tr> <tr> <td>10 CFR 35.100, SCHEDULE A, GROUP III</td> <td></td> <td></td> </tr> <tr> <td>10 CFR 35.100, SCHEDULE A, GROUP IV</td> <td></td> <td>AS NEEDED</td> </tr> <tr> <td>10 CFR 35.100, SCHEDULE A, GROUP V</td> <td></td> <td>AS NEEDED</td> </tr> <tr> <td>10 CFR 35.100, SCHEDULE A, GROUP VI</td> <td></td> <td></td> </tr> </tbody> </table>	RADIOACTIVE MATERIAL LISTED IN:	ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS (In millicuries)	10 CFR 31.11 FOR IN VITRO STUDIES			10 CFR 35.100, SCHEDULE A, GROUP I		AS NEEDED	10 CFR 35.100, SCHEDULE A, GROUP II		AS NEEDED	10 CFR 35.100, SCHEDULE A, GROUP III			10 CFR 35.100, SCHEDULE A, GROUP IV		AS NEEDED	10 CFR 35.100, SCHEDULE A, GROUP V		AS NEEDED	10 CFR 35.100, SCHEDULE A, GROUP VI			<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 40%;">ADDITIONAL ITEMS:</th> <th style="width: 10%;">MARK ITEMS DESIRED "X"</th> <th style="width: 10%;">MAXIMUM POSSESSION LIMITS (In millicuries)</th> </tr> </thead> <tbody> <tr> <td>IODINE-131 AS IODIDE FOR TREATMENT OF HYPERTHYROIDISM</td> <td></td> <td></td> </tr> <tr> <td>PHOSPHORUS-32 AS SOLUBLE PHOSPHATE FOR TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA AND BONE METASTASES</td> <td></td> <td></td> </tr> <tr> <td>PHOSPHORUS-32 AS COLLOIDAL CHROMIC PHOSPHATE FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.</td> <td></td> <td></td> </tr> <tr> <td>GOLD-198 AS COLLOID FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.</td> <td></td> <td></td> </tr> <tr> <td>IODINE-131 AS IODIDE FOR TREATMENT OF THYROID CARCINOMA</td> <td></td> <td></td> </tr> <tr> <td>XENON-133 AS GAS OR GAS IN SALINE FOR BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES.</td> <td></td> <td></td> </tr> </tbody> </table>	ADDITIONAL ITEMS:	MARK ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS (In millicuries)	IODINE-131 AS IODIDE FOR TREATMENT OF HYPERTHYROIDISM			PHOSPHORUS-32 AS SOLUBLE PHOSPHATE FOR TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA AND BONE METASTASES			PHOSPHORUS-32 AS COLLOIDAL CHROMIC PHOSPHATE FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.			GOLD-198 AS COLLOID FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.			IODINE-131 AS IODIDE FOR TREATMENT OF THYROID CARCINOMA			XENON-133 AS GAS OR GAS IN SALINE FOR BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES.		
RADIOACTIVE MATERIAL LISTED IN:	ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS (In millicuries)																																												
10 CFR 31.11 FOR IN VITRO STUDIES																																														
10 CFR 35.100, SCHEDULE A, GROUP I		AS NEEDED																																												
10 CFR 35.100, SCHEDULE A, GROUP II		AS NEEDED																																												
10 CFR 35.100, SCHEDULE A, GROUP III																																														
10 CFR 35.100, SCHEDULE A, GROUP IV		AS NEEDED																																												
10 CFR 35.100, SCHEDULE A, GROUP V		AS NEEDED																																												
10 CFR 35.100, SCHEDULE A, GROUP VI																																														
ADDITIONAL ITEMS:	MARK ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS (In millicuries)																																												
IODINE-131 AS IODIDE FOR TREATMENT OF HYPERTHYROIDISM																																														
PHOSPHORUS-32 AS SOLUBLE PHOSPHATE FOR TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA AND BONE METASTASES																																														
PHOSPHORUS-32 AS COLLOIDAL CHROMIC PHOSPHATE FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.																																														
GOLD-198 AS COLLOID FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.																																														
IODINE-131 AS IODIDE FOR TREATMENT OF THYROID CARCINOMA																																														
XENON-133 AS GAS OR GAS IN SALINE FOR BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES.																																														
6.b. RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Sealed sources up to 3 mCi used for calibration and reference standards are authorized under Section 35.14(d), 10 CFR Part 35, and NEED NOT BE LISTED.)																																														
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;">ELEMENT AND MASS NUMBER</th> <th style="width: 20%;">CHEMICAL AND/OR PHYSICAL FORM</th> <th style="width: 20%;">MAXIMUM NUMBER OF MILLICURIES OF EACH FORM</th> <th style="width: 30%;">DESCRIBE PURPOSE OF USE</th> </tr> </thead> <tbody> <tr> <td style="height: 100px;"></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>	ELEMENT AND MASS NUMBER	CHEMICAL AND/OR PHYSICAL FORM	MAXIMUM NUMBER OF MILLICURIES OF EACH FORM	DESCRIBE PURPOSE OF USE																																										
ELEMENT AND MASS NUMBER	CHEMICAL AND/OR PHYSICAL FORM	MAXIMUM NUMBER OF MILLICURIES OF EACH FORM	DESCRIBE PURPOSE OF USE																																											

INFORMATION REQUIRED FOR ITEMS 7 THROUGH 23

For Items 7 through 23, check the appropriate box(es) and submit a detailed description of all the requested information. Begin each item on a separate sheet. Identify the item number and the date of the application in the lower right corner of each page. If you indicate that an appendix to the medical licensing guide will be followed, do not submit the pages, but specify the revision number and date of the referenced guide: Regulatory Guide 10.8 , Rev. _____ Date: _____

7. MEDICAL ISOTOPES COMMITTEE <input checked="" type="checkbox"/> Names and Specialties Attached; and Duties as in Appendix B; or _____ (Check One) Equivalent Duties Attached		15. GENERAL RULES FOR THE SAFE USE OF RADIOACTIVE MATERIAL (Check One) Appendix G Rules Followed; or Equivalent Rules Attached	
8. TRAINING AND EXPERIENCE Supplements A & B Attached for Each Individual User; and Supplement A Attached for RSO.		16. EMERGENCY PROCEDURES (Check One) Appendix H Procedures Followed; or Equivalent Procedures Attached	
9. INSTRUMENTATION (Check One) Appendix C Form Attached; or List by Name and Model Number		17. AREA SURVEY PROCEDURES (Check One) Appendix I Procedures Followed; or Equivalent Procedures Attached	
10. CALIBRATION OF INSTRUMENTS Appendix D Procedures Followed for Survey Instruments; or _____ (Check One) Equivalent Procedures Attached; and Appendix D Procedures Followed for Dose Calibrator; or _____ (Check One) Equivalent Procedures Attached		18. WASTE DISPOSAL (Check One) Appendix J Form Attached; or Equivalent Information Attached	
11. FACILITIES AND EQUIPMENT Description and Diagram Attached		19. THERAPEUTIC USE OF RADIOPHARMACEUTICALS (Check One) Appendix K Procedures Followed; or Equivalent Procedures Attached	
12. PERSONNEL TRAINING PROGRAM Description of Training Attached		20. THERAPEUTIC USE OF SEALED SOURCES Detailed Information Attached; and Appendix L Procedures Followed; or _____ (Check One) Equivalent Procedures Attached	
13. PROCEDURES FOR ORDERING AND RECEIVING RADIOACTIVE MATERIAL Detailed Information Attached		21. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE GASES (e.g., Xenon - 133) Detailed Information Attached	
14. PROCEDURES FOR SAFELY OPENING PACKAGES CONTAINING RADIOACTIVE MATERIALS (Check One) Appendix F Procedures Followed; or Equivalent Procedures Attached		22. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL IN ANIMALS Detailed Information Attached	
		23. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL SPECIFIED IN ITEM 6.b Detailed Information Attached	

24. PERSONNEL MONITORING DEVICES

TYPE (Check appropriate box)		SUPPLIER	EXCHANGE FREQUENCY
a. WHOLE BODY	FILM		
	TLD		
	OTHER (Specify)		
b. FINGER	FILM		
	TLD		
	OTHER (Specify)		
c. WRIST	FILM		
	TLD		
	OTHER (Specify)		

d. OTHER (Specify)


25. FOR PRIVATE PRACTICE APPLICANTS ONLY

a. HOSPITAL AGREEING TO ACCEPT PATIENTS CONTAINING RADIOACTIVE MATERIAL		b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR.
NAME OF HOSPITAL N/A		
MAILING ADDRESS		
CITY	STATE	ZIP CODE
c. WHEN REQUESTING THERAPY PROCEDURES, ATTACH A COPY OF RADIATION SAFETY PRECAUTIONS TO BE TAKEN AND LIST AVAILABLE RADIATION DETECTION INSTRUMENTS.		

26. CERTIFICATE

(This item must be completed by applicant)

The applicant and any official executing this certificate on behalf of the applicant named in Item 1a certify that this application is prepared in conformity with Title 10, Code of Federal Regulations, Parts 30 and 35, and that all information contained herein, including any supplements attached hereto, is true and correct to the best of our knowledge and belief.

a. LICENSE FEE REQUIRED (See Section 170.31, 10 CFR 170)	b. APPLICANT OR CERTIFYING OFFICIAL (Signature) 
	(1) NAME (Type of Print) A. Paul Kidd
(1) LICENSE FEE CATEGORY: Exempt	(2) TITLE Medical Center Director
(2) LICENSE FEE ENCLOSED: \$	c. DATE 4/17/86

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

29-17045-01

Docket or Reference number

030-12104

Amendment No. 06

V. A. Medical Center
Lyons, New Jersey 07939

In accordance with letter dated August 12, 1985, License Number 29-17045-01 is amended as follows:

Items 6., 7., 8. and 9. are amended to read:

- | | | |
|--|--|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
| A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35 | A. Any radio-pharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35 | A. As necessary for uses authorized in Subitem 9.A. |
| B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35 | B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35 | B. 2 curies of each byproduct material authorized in Subitem 6.B. |
| C. Any byproduct material listed in Section 31.11(a) of 10 CFR 31 | C. Any | C. 3 millicuries of each byproduct material authorized in Subitem 6.C. |

9. Authorized use

- A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 Title 10, Code of Federal Regulations.
- B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- C. In vitro studies.

~~551000-530~~
2pp

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

29-17045-01

Docket or Reference number

03C-12104

Amendment No. 06

CONDITIONS

Condition 12. is amended to read:

12. Licensed material shall be used by, or under the supervision of, Arnold Olefson, M.D.

Groups I, II and III

In vitro studies.



For the U.S. Nuclear Regulatory Commission

Date

SEP 24 1985

By

Edwin A. Wurtz

Nuclear Materials Safety and
Safeguards Branch, Region I
King of Prussia, Pennsylvania 19406